Sandoz’s Saynor Sees Tipping Point For Biosimilars
Several Factors Are Combining To Push Industry Forward, Says Sandoz CEO
A combination of factors – including recent moves in the UK to broaden access to biosimilars for rheumatoid arthritis patients, as well as the new MHRA pathway for biosimilars and a growing call for global regulatory alignment – are contributing to a “biosimilar Zeitgeist” that could see long-in-the-making change coming for the industry, according to Sandoz CEO Richard Saynor.
